W2O has bought US-based advertising and medical education 21GRAMS, expanding its direct-to-consumer, direct-to-provider and business-to-business advertising and marketing operations.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh